Latest Breaking News On - Martin grobusch - Page 1 : comparemela.com

Sanaria researchers make progress in the development of highly protective malaria vaccine Researchers from Sanaria ® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines. In an article published today in Nature, Sanaria s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration. The variant parasite used in the trial is a Brazilian malaria parasite genetically more variant from the African parasites in the vaccine than 700 malaria parasites from Africa. Protection was achieved at a dose that is 20% of the company s first-generation malaria vaccine dosage.

Noord hollandHolm kellerSanaria pfMartin grobuschStephenl hoffmanEmily hendersonAmsterdam university medical centersNational institutes of healthEu malaria fundHead of the centerInternational pfspz consortiumNational institutesProfessor martin grobuschTropical medicineTravel medicineAmsterdam university medical